The 2021 update of the study confirmed the promising results, with a 65% ORR (44% CR, 12% CRi, and 6% MLFS); in the subset of TP53-mutated AML, the ORR was 71% (48% CR, 19% CRi, and 5% MLFS) [99]. This evidence concerns the gene TP53 and acute myeloid leukemia.